Industry Focus

Novartis nabs approval for a drug that could revolutionize how we treat heart disease and CVS Health doubles down on its anti-tobacco stance. Our Motley Fool's Michael Douglass and Todd Campbell discuss what it means for the companies involved.

Direct download: 150708_IF_Healthcare.mp3
Category:Podcast -- posted at: 4:54pm EDT

1